Literature DB >> 9279335

Invasive pneumococcal infections. A comparison between adults and children.

G Rahav1, Y Toledano, D Engelhard, A Simhon, A E Moses, T Sacks, M Shapiro.   

Abstract

A similar number of adults and children had invasive pneumococcal infection. There was male predominance, and different ethnic distribution between children and adults. The majority of adults (78%), had underlying diseases, but this was less frequent in children (24%). The presenting illness differed between adults and children. Complications of invasive pneumococcal infection occurred more frequently in adults than in children. The mortality rate in adults was 21.5%; in children, only 3.8%. The rate of penicillin-resistant pneumococci at our hospital was 23%, while cefotaxime resistance was 4.2%. Penicillin-resistant pneumococci were not isolated more frequently from children than from adults. Patients with penicillin-resistant pneumococci had longer duration of hospitalization and more nosocomially acquired infections. No difference in the mortality rate was found between patients with resistant or sensitive pneumococci. Ninety-five percent of strains were included in the current vaccine, but less than 2% of patients had been vaccinated. Isolates prevalent in Europe and the United States (19, 5, 1, 14, 6, 18, 12, 4, 9, 23, 7) were also most prevalent in Jerusalem. The distribution of serotypes differed between children and adults, and between patients from whom resistant organisms were isolated as opposed to sensitive organisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279335     DOI: 10.1097/00005792-199707000-00007

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  9 in total

1.  Influence of patient age on Streptococcus pneumoniae serotypes causing invasive disease.

Authors:  J Inostroza; A M Vinet; G Retamal; P Lorca; G Ossa; R R Facklam; R U Sorensen
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis       Date:  2002-01

3.  It's time to step up the management of community-acquired pneumonia.

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2002-03       Impact factor: 1.798

4.  Ten-year surveillance of pneumococcal infections in Temuco, Chile: implications for vaccination strategies.

Authors:  Jaime Inostroza; Vijna Illesca; Patricia Reydet; Ana Maria Vinet; Gonzalo Ossa; Sergio Muñoz; Terry Thompson; Ricardo U Sorensen
Journal:  Clin Vaccine Immunol       Date:  2007-03-28

5.  Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza.

Authors:  Asa Karlström; Kelli L Boyd; B Keith English; Jonathan A McCullers
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

6.  Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza.

Authors:  Matthew W Smith; Jeffrey E Schmidt; Jerold E Rehg; Carlos J Orihuela; Jonathan A McCullers
Journal:  Comp Med       Date:  2007-02       Impact factor: 0.982

7.  Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types.

Authors:  Donald Inverarity; Karen Lamb; Mathew Diggle; Chris Robertson; David Greenhalgh; Tim J Mitchell; Andrew Smith; Johanna M C Jefferies; Stuart C Clarke; Jim McMenamin; Giles F S Edwards
Journal:  J Med Microbiol       Date:  2011-03-10       Impact factor: 2.472

8.  Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004).

Authors:  S Afifi; M O Wasfy; M A Azab; F G Youssef; G Pimentel; T W Graham; H Mansour; N Elsayed; K Earhart; R Hajjeh; F Mahoney
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-05       Impact factor: 5.103

9.  The relative resistance of children to sepsis mortality: from pathways to drug candidates.

Authors:  Rose B Joachim; Gabriel M Altschuler; John N Hutchinson; Hector R Wong; Winston A Hide; Lester Kobzik
Journal:  Mol Syst Biol       Date:  2018-05-17       Impact factor: 11.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.